Ergomed plc Total Voting Rights (5093R)
March 01 2019 - 2:00AM
UK Regulatory
TIDMERGO
RNS Number : 5093R
Ergomed plc
01 March 2019
PRESS RELEASE
FOR IMMEDIATE RELEASE
Total Voting Rights
Guildford, UK - 1 March 2019: In accordance with the Financial
Conduct Authority's Disclosure Guidance and Transparency Rules
(DTRs), Ergomed plc (the "Company") announces the following
information.
The Company's issued share capital as at 28 February 2019
consisted of 46,141,438 ordinary shares of 1p each, none of which
were held in treasury. Each ordinary share in the capital of the
Company carries one voting right.
The above figure may be used by shareholders as the denominator
for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest
in, the Company, under the DTRs.
- Ends -
Enquiries:
Ergomed plc Tel: +44 (0) 1483 402
975
Miroslav Reljanovic (Executive Chairman)
Stuart Jackson (Chief Financial Officer)
Numis Securities Limited Tel: +44 (0) 20 7260 1000
Michael Meade / Freddie Barnfield (Nominated
Adviser)
James Black (Joint Broker)
Consilium Strategic Communications - for Tel: +44 (0) 20 3709 5700
UK enquiries
Chris Gardner / Mary-Jane Elliott ergomed@consilium-comms.com
Matthew Neal / Olivia Manser
MC Services - for Continental European enquiries Tel: +49 211 5292 5222
Anne Hennecke
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical
industry spanning all phases of clinical development, post-approval
pharmacovigilance and medical information. Ergomed's fast-growing,
profitable services offering encompasses a complete suite of
specialist pharmacovigilance solutions, integrated under the
PrimeVigilance brand, in addition to a full range of high quality
contract research and trial management services (CRO). Leveraging
its CRO expertise, Ergomed also has a drug development portfolio of
co-development partnerships and wholly-owned programmes. For
further information, visit: http://ergomedplc.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TVRTPMRTMBATBJL
(END) Dow Jones Newswires
March 01, 2019 02:00 ET (07:00 GMT)
Ergomed (LSE:ERGO)
Historical Stock Chart
From Apr 2024 to May 2024
Ergomed (LSE:ERGO)
Historical Stock Chart
From May 2023 to May 2024